Despite a steady improvement in the results of treatment of childhood T-cell I,mphoblastic lywmphoma over the past 20 vears, overall 30-4000 of patients still relapse. Ideally, one would like to be able to predict which subgroup will have a poor outcome either before treatment or shortly after standard therapy has started. Early recognition of these children would allow the use of a more intensive treatment protocol introducing different drugs and perhaps high-dose chemotherapy with bone marrow rescue. or addition of local treatment such as mediastinal irradiation.
It is now established that T-cell lymphoblastic lymphoma and T-cell acute l'mphoblastic leukaemia (T-ALL) are different parts of a disease spectrum. the latter diagnosis being defined arbitrarily when the bone marrow contains more than 25°0o lymphoblasts. With the exception of advanced stage at presentation. the use of patient characteristics, cell markers. immunocv'tochemistr-and immunophenotyping have failed to provide a consistentlv reliable index of poor prognosis (Crist et al.. 1988 : Berger et al.. 1990 : Pui et al.. 1990 : Shuster et al.. 1990 ). It remains possible that the use of high resolution cytogenetics or molecular markers may yet be able to define precise abnormalities which can be used to select treatment regimens (Lange et al.. 1992 ). The United Kingdom Children's Cancer Study Group (UKCCSG) study 8503 in advanced stage childhood T-cell ly'mphoblastic ly'mphoma (Eden et al.. 1992 ) is one of the largest published using a single treatment protocol (Figure 1) for this rare malignancy. In summary. it comprised treatment induction with weekly intravenous (i.v.) Clearly this retrospective analysis has limitations, as by definition any data obtained in this way can only be safely used to generate a hypothesis which then has to be tested prospectively. To try to improve the discrimination using speed of response of mediastinal disease in these patients. it is planned to incorporate a series of carefully timed PA CXRs into a future study. In addition. thoracic computerised axial tomography will be performed. in order to try to improve the accuracy of assessing treatment response and to evaluate the feasibility of guided fine-needle aspirates to look for residual disease. The results will enable us to investigate further the potential of this possible prognostic factor.
In conclusion, clinical and radiological parameters on all 78 stage III patients with confirmed T-cell lymphoblastic lymphoma who were treated on UKCCSG study 8503 have been collected and analysed retrospectively. A significant 5 year event-free and overall survival benefit have been demonstrated for those patients whose mediastinal masses completely resolved by 60 days from the start of treatment using plain PA CXR assessment. This simple measure of response to chemotherapy may prove to be of use in modifying treatment early on in patients who have persistent mediastinal abnormalities. in an attempt to improve the cure rate in this rare paediatric malignancy.
